HLA 1 & 2 (Donor) HLA Tissue Typing at Test Zone Diagnostic Center

HLA 1 & 2 (Donor) HLA Tissue Typing at Test Zone Diagnostic Center

HLA 1 & 2 (Donor) HLA Tissue Typing at Test Zone Diagnostic Center is a highly specialized molecular diagnostic test designed to evaluate the compatibility between an organ or stem cell donor and a recipient. Human Leukocyte Antigens (HLA) are proteins found on the surface of nearly all nucleated cells in the human body. These proteins are coded by the Major Histocompatibility Complex (MHC) located on chromosome 6. The primary function of HLA proteins is to help the immune system distinguish between the body’s own cells and foreign invaders. When a transplant is performed, the recipient’s immune system may recognize the donor’s HLA proteins as foreign, triggering an immune response that can lead to graft rejection. Conversely, in stem cell transplants, the donor’s immune cells may attack the recipient’s tissues, a life-threatening condition known as Graft-versus-Host Disease (GvHD). Therefore, precise HLA typing of both the donor and recipient is the cornerstone of transplant medicine.

This advanced laboratory investigation utilizes state-of-the-art molecular biology techniques, including Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS), to identify specific HLA alleles. HLA antigens are broadly classified into two groups: Class I (which includes HLA-A, HLA-B, and HLA-C) and Class II (which includes HLA-DR, HLA-DQ, and HLA-DP). Class I antigens are expressed on all nucleated cells and present endogenous peptides to CD8+ cytotoxic T cells, while Class II antigens are primarily expressed on antigen-presenting cells and present exogenous peptides to CD4+ helper T cells. By performing high-resolution HLA typing, Test Zone Diagnostic Center in Lahore, Pakistan, provides transplant teams with the detailed genetic profile required to assess immunological risk, calculate match grades, and design post-transplant immunosuppressive regimens, significantly improving long-term graft survival and patient outcomes.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is essential to ensure the accuracy of molecular HLA typing. Patients and donors undergoing this test should observe the following guidelines:

• No Fasting Required: There is no need to fast before the blood draw. Donors can eat and drink normally.
• Disclose Medical History: It is critical to inform the laboratory staff if the donor has received a blood transfusion within the last three months. Transfused blood contains white blood cells from the donor, which can introduce foreign DNA and interfere with molecular testing results.
• Disclose Prior Transplants: Inform the clinical team of any history of bone marrow or stem cell transplantation, as this alters the circulating cellular DNA profile.
• Medication Reporting: Continue taking regular medications unless specifically instructed otherwise by the physician, but disclose any immunosuppressive therapy.
• Hydration: Drink plenty of water before the procedure to ensure optimal vein accessibility and a smooth venipuncture process.

During the Procedure

The collection of the sample for HLA typing is a routine, safe, and standardized laboratory procedure:

• Patient Identification: The phlebotomist will verify the donor’s identity using official identification documents to ensure absolute accuracy in transplant records.
• Venipuncture Site Selection: The donor will sit comfortably, and the phlebotomist will locate a suitable vein, typically in the antecubital fossa of the arm.
• Sanitization: The skin over the selected vein is thoroughly cleaned with an antiseptic solution to prevent contamination.
• Sample Collection: A sterile needle is inserted into the vein, and blood is collected into specialized tubes containing Acid Citrate Dextrose (ACD) or Ethylenediaminetetraacetic Acid (EDTA). Heparin tubes are strictly avoided as heparin can inhibit the PCR amplification process.
• Duration: The entire blood collection process takes approximately five to ten minutes.
• Post-Collection Care: Gentle pressure is applied to the puncture site with a sterile cotton ball, followed by the application of a bandage to prevent bruising.
• Safety and Comfort: The procedure is performed under strict aseptic conditions using single-use, disposable needles, eliminating any risk of infection.

When is a HLA 1 & 2 (Donor) HLA Tissue Typing Performed?

Renal Transplantation Evaluation

End-stage renal disease (ESRD) resulting from diabetes, chronic glomerulonephritis, or severe hypertension requires renal transplantation as a definitive treatment. Patients experience symptoms such as severe uremia, fluid overload, and profound fatigue. Physicians request HLA 1 & 2 (Donor) HLA Tissue Typing for potential living donors (often family members) to compare their HLA profiles with the recipient’s. A closer HLA match reduces the likelihood of acute cellular rejection and antibody-mediated rejection, ensuring the long-term viability of the transplanted kidney.

Hematopoietic Stem Cell Transplantation

Patients suffering from hematological malignancies like acute myeloid leukemia, lymphoma, or bone marrow failure syndromes such as aplastic anemia require hematopoietic stem cell transplantation (HSCT). Symptoms include severe anemia, recurrent infections, and unexplained bleeding. High-resolution HLA typing of potential donors is critical in this scenario. A perfect 10/10 or 8/8 match at the allele level (HLA-A, -B, -C, -DRB1, and -DQB1) is sought to minimize the risk of Graft-versus-Host Disease (GvHD), where the donor’s reconstituted immune system attacks the recipient’s vital organs.

Living Liver Donor Assessment

For patients with end-stage liver cirrhosis or acute liver failure presenting with jaundice, ascites, and hepatic encephalopathy, a living donor liver transplant is a life-saving option. Although liver transplants are less dependent on HLA matching than kidney transplants due to the liver’s unique immunological tolerance, HLA tissue typing is still performed. It helps identify pre-existing donor-specific antibodies (DSA) in the recipient and assists in assessing the overall immunological risk, especially in highly sensitized pediatric patients.

Familial Donor Screening

When a patient is identified as a transplant candidate, immediate family members, including siblings, parents, and children, are screened. Because HLA genes are inherited co-dominantly as haplotypes (one set from each parent), siblings have a 25% chance of being a perfect HLA match, a 50% chance of being a half (haploidentical) match, and a 25% chance of being completely mismatched. HLA tissue typing of family members is performed to identify the most compatible donor rapidly, avoiding the prolonged search for an unrelated donor in international registries.

Pre-emptive Immunological Risk Stratification

In cases where a recipient has undergone multiple previous transplants, pregnancies, or blood transfusions, they may have developed a high level of anti-HLA antibodies (sensitization). HLA tissue typing of potential donors is performed to cross-reference the donor’s HLA antigens against the recipient’s panel-reactive antibodies (PRA). This allows transplant cardiologists, nephrologists, and immunologists to predict and avoid hyperacute rejection, ensuring that the selected donor does not possess antigens against which the recipient has pre-existing antibodies.

What Does a HLA 1 & 2 (Donor) HLA Tissue Typing Detect?

HLA 1 & 2 (Donor) HLA Tissue Typing detects the specific genetic alleles and corresponding surface proteins that define an individual’s tissue type. The test identifies and characterizes the following parameters:

• Specific alleles at the HLA-A locus (Class I)
• Specific alleles at the HLA-B locus (Class I)
• Specific alleles at the HLA-C locus (Class I)
• Specific alleles at the HLA-DRB1 locus (Class II)
• Specific alleles at the HLA-DQB1 locus (Class II)
• Specific alleles at the HLA-DPB1 locus (Class II)
• Low-resolution antigen-level matches (e.g., HLA-A2)
• High-resolution allele-level matches (e.g., HLA-A*02:01)
• Homozygosity or heterozygosity at each HLA locus
• Haploidentical match status between parents and children
• Syngeneic match status in the case of identical twins
• Presence of HLA-B*27 (associated with ankylosing spondylitis risk)
• Presence of HLA-DRB1*15:01 (associated with multiple sclerosis risk)
• Presence of HLA-DQ2.5 or HLA-DQ8 (associated with celiac disease risk)
• Presence of HLA-B*57:01 (predictive of severe abacavir drug hypersensitivity)
• Presence of HLA-B*58:01 (predictive of allopurinol-induced Stevens-Johnson syndrome)
• Presence of HLA-A*31:01 (predictive of carbamazepine hypersensitivity)
• Mismatched HLA loci count between donor and recipient
• Non-inherited maternal antigens (NIMA) for haploidentical matching
• Non-inherited paternal antigens (NIPA) for haploidentical matching
• Donor-specific antibody target antigens
• Secondary HLA-DRB3, DRB4, and DRB5 locus alleles
• Overall histocompatibility index and compatibility grade

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center, we understand that transplant evaluations are highly time-sensitive. Because HLA tissue typing involves complex molecular assays, including DNA extraction, PCR amplification, and hybridization or sequencing, the turnaround time typically ranges from 5 to 10 working days. This timeline ensures that every step of the molecular analysis undergoes rigorous quality control to guarantee absolute accuracy. Once the analysis is complete, the detailed histocompatibility report is reviewed and signed by an experienced molecular pathologist. Patients and transplant coordinators can access reports securely online through the Test Zone Diagnostic Center web portal, receive them via email, or collect printed copies directly from our facility in Lahore.

HLA 1 & 2 (Donor) HLA Tissue Typing Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
HLA-A Locus (Class I)	Normal expression of standard maternal and paternal HLA-A alleles	Mismatched HLA-A alleles relative to the recipient; rare allelic variants
HLA-B Locus (Class I)	Standard distribution of HLA-B alleles consistent with population genetics	Presence of HLA-B*57:01 (hypersensitivity marker); mismatched alleles
HLA-C Locus (Class I)	Normal expression of HLA-C alleles	Allelic mismatching leading to increased natural killer (NK) cell activation
HLA-DRB1 Locus (Class II)	Standard expression of HLA-DRB1 alleles	High-risk mismatches; presence of alleles associated with autoimmune susceptibility
HLA-DQB1 Locus (Class II)	Normal expression of HLA-DQB1 alleles	Mismatched DQ alleles; presence of HLA-DQ2/DQ8 (celiac disease markers)
Match Grade (Stem Cell)	10/10 or 8/8 high-resolution allelic match	9/10, 8/10, or lower match (increased risk of graft failure or GvHD)
Match Grade (Solid Organ)	6/6 or high-grade antigen match	Multiple HLA mismatches requiring intensive post-transplant immunosuppression
Homozygosity Status	Heterozygous alleles at all loci (normal genetic diversity)	Homozygosity at specific loci, reducing matching complexity but indicating low diversity

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for HLA 1 & 2 (Donor) HLA Tissue Typing?

• Experienced Healthcare Professionals: Our molecular pathology department is led by highly qualified pathologists and immunologists specializing in histocompatibility testing.
• Patient-Focused Care: We prioritize donor comfort and clarity throughout the blood collection and testing process.
• Quality Diagnostic Services: Test Zone Diagnostic Center adheres to international quality standards for molecular and genetic testing.
• Professional Reporting: We provide comprehensive, easy-to-interpret HLA reports detailing low and high-resolution alleles.
• Modern Diagnostic Approach: We utilize advanced PCR and molecular technologies to ensure high-precision typing.
• Comfortable Environment: Our state-of-the-art facility in Lahore offers a clean, professional, and welcoming atmosphere.
• Convenient Location: Easily accessible location in Lahore, facilitating prompt sample collection for local and out-of-city donors.
• Commitment to Accurate Diagnosis: We implement rigorous quality control protocols to deliver reliable results for critical transplant decisions.